☆ 4.7 Article

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants

EMERGING MICROBES & INFECTIONS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pathology

Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas

Paul A. Christensen et al.

Summary: The Omicron variant of SARS-CoV-2 has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases. A study found that patients infected with Omicron were younger, had higher vaccine breakthrough rates, and were less likely to be hospitalized compared to patients with other variants. They also required less respiratory support and had shorter hospital stays, indicating reduced disease severity.

AMERICAN JOURNAL OF PATHOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Laura Vangeel et al.

Summary: Remdesivir and its parent nucleoside, molnupiravir and its parent nucleoside, and the viral protease inhibitor nirmatrelvir have equipotent antiviral activity against the ancestral SARS-CoV2 strain and the variants of concern including Omicron.

ANTIVIRAL RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai et al.

Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.

CELL (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

Hong-jie Qian et al.

Summary: VV116, an oral drug candidate against SARS-CoV-2, showed satisfactory safety and tolerability in healthy subjects, with no significant impact from food intake. These findings support further investigation of VV116 in patients with COVID-19.

ACTA PHARMACOLOGICA SINICA (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later

Sirina Ekpanyapong et al.

Summary: COVID-19 patients exhibit various hepato-biliary manifestations, including infrequent and chronic cholangiopathy. The etiology of liver injury is multifactorial, with limited evidence of direct SARS-CoV-2 infection of the liver. Patients with liver diseases should approach COVID-19 cautiously, and vaccination is strongly recommended.

JOURNAL OF VIRAL HEPATITIS (2022)

添加到收藏夹

Letter Medicine, General & Internal

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Letter Cell Biology

Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2

Yuanchao Xie et al.

CELL RESEARCH (2021)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Liver injury in COVID-19: management and challenges

Chao Zhang et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.